PT  - JOURNAL ARTICLE
AU  - Ethawi, Yahya
AU  - Hussain, Abrar
AU  - Minski, John
AU  - Miller, Joe
AU  - Alvaro, Ruben
TI  - LARGE VOLUME SURFACTANT ADMINISTRATION IN PREMATURE INFANTS LESS THAN 35 WEEKS USING MINIMALLY INVASIVE SURFACTANT THERAPY
AID  - 10.1101/2022.08.20.22278507
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.20.22278507
4099  - http://medrxiv.org/content/early/2022/08/22/2022.08.20.22278507.short
4100  - http://medrxiv.org/content/early/2022/08/22/2022.08.20.22278507.full
AB  - Large volume surfactant administration in premature infants less than 35 weeks using minimally invasive surfactant therapy (MIST).Background Surfactant in small volume preparations can be successfully administered to premature infants using a narrow-bore vascular catheter inserted into the trachea under direct vision. It was not known if surfactant in large volume preparations could be administered effectively to spontaneously breathing premature infants while maintaining them on nasal continuous positive airway pressure (nCPAP).Objective To evaluate the feasibility of administering a large volume of surfactant (5 ml/kg) in spontaneously breathing premature infants on nCPAP using a vascular catheter.Methods Single-arm interventional trial in two level III nurseries in Canada. Spontaneously breathing premature infants between 24 and 34 weeks’ gestation, born between July 4th, 2012 and September 5th, 2012 were eligible for the trial in the first 24 hours of life. A 16-gauge vascular catheter was inserted under direct vision through the vocal cords to administer 5 ml/kg of surfactant while maintaining the infants on nCPAP.Results Twenty-one premature infants were enrolled. The mean gestational age was 29 ± 3 (range 24 to 34 weeks) with mean birth weight of 1474 ± 575 g. Surfactant was successfully administered in 20 infants (95 %). There was a clear effect after surfactant administration with a decrease in oxygen requirement from 0.34 ± 0.111 before the procedure, to 0.26 ± 0.08 after the procedure (p = .001), and a decrease in nCPAP pressure from 7.2 ± 0.5 cm H2O before the procedure to 5.9 ± 0.5 after the procedure (p < .0001). The mean duration for surfactant administration was 8.3 ± 3.4 minutes. The procedure was temporarily stopped in three cases due to bradycardia and/or apnea with desaturations that spontaneously recovered without intervention. Coughing and reflux of the surfactant were transiently observed in four cases (19 %).Conclusion It is feasible to administer large volumes of surfactant without interrupting nCPAP via a vascular catheter, to premature infants less than 35 weeks’ gestation. Further trials are needed to confirm the safety and efficacy of this method compared to other methods of surfactant administration.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01553292Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT01553292?cond=ECALMIST&draw=2&rank=2 Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:"This was a prospective non-randomized feasibility clinical trial conducted at two centers (Health Sciences Centre, and the St. Boniface General Hospital) in Winnipeg, Manitoba, Canada. The study was approved by the research ethics committees in the two centers and by the faculty committee for the use of human subjects in researchI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors